FTSE gains on optimism a Covid-19 vaccine could be approved this week

FTSE 100 headed higher at start of the week thanks to progress on the vaccine front and reports that the November lockdown cut coronavirus infections by a third. London's leading index advanced 4 points to 6,372 in early trading.  

The UK is expected to authorise the COVID-19 vaccine candidate developed by Pfizer Inc. (NYSE:PFE) and BioNTech this week. The rollout could start as early as December 7, while the country has secured 40mln doses.  

Frasers Group PLC (LON:FRAS), the sports retail group run by Mike Ashley, has offered funding of up to £50mln to struggling retailer Arcadia Group. The Topshop owner is facing administration as early as Monday, risking 13,000 jobs.  

HSBC Holdings PLC (LON:HSBA) is mulling a complete exit from its US retail banking operations. The FTSE 100 firm has been struggling to compete with much bigger players in the country.  

Symphony Environmental Technologies PLC (LON:SYM) shares shot after a highly successful coronavirus (COVID-19) test of anti-viral gloves and masks containing the company’s d2pAM antimicrobial technology. The assessment was carried out in Brazil.

CentralNic Group PLC saw revenue more than double year-on-year in the first nine months of 2020, with record organic revenue growth of 17%. The internet platform operator posted revenue up 118%.

Scotgold Resources Ltd (LON:SGZ) is on course to start Phase 1 production at the Cononish gold and silver mine in the Trossachs later today. This phase targets average annual gold equivalent production of 9,910 ounces.

Quick facts: Pfizer

Price: 36.66 USD

Market: NYSE
Market Cap: $203.85 billion


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Shield Therapeutics remain optimistic about US commercialisation of Accrufer...

Shield Therapeutics PLC (LON:STX) Chief Executive Tim Watts joins Proactive London's Katie Pilbeam to discuss their financial and operational update. Watts highlights the European sales volumes of its breakthrough iron deficiency drug Feraccru which grew by 70% year-on-year. He...

4 hours, 42 minutes ago

2 min read